

Sean J Pittock

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5334463/publications.pdf>

Version: 2024-02-01

289
papers

30,840
citations

5268

83
h-index

5120

166
g-index

295
all docs

295
docs citations

295
times ranked

12072
citing authors

#	ARTICLE	IF	CITATIONS
1	Optic chiasm involvement in AQP-4 antibodyâ€“positive NMO and MOG antibodyâ€“associated disorder. Multiple Sclerosis Journal, 2022, 28, 149-153.	3.0	24
2	Comparison of immune checkpoint inhibitor-related neuropathies among patients with neuroendocrine and non-neuroendocrine tumours. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 112-114.	1.9	13
3	Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension. Multiple Sclerosis Journal, 2022, 28, 480-486.	3.0	32
4	Exposure to TNF inhibitors is rare at MOGAD presentation. Journal of the Neurological Sciences, 2022, 432, 120044.	0.6	7
5	Spectrum of sublytic astrocytopathy in neuromyelitis optica. Brain, 2022, 145, 1379-1390.	7.6	18
6	AQP4-IgG-seronegative patient outcomes in the N-MOMentum trial of inebilizumab in neuromyelitis optica spectrum disorder. Multiple Sclerosis and Related Disorders, 2022, 57, 103356.	2.0	16
7	Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder. Neurology and Therapy, 2022, 11, 123-135.	3.2	21
8	LGII antibody encephalitis: acute treatment comparisons and outcome. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 309-315.	1.9	48
9	OCT retinal nerve fiber layer thickness differentiates acute optic neuritis from MOG antibody-associated disease and Multiple Sclerosis. Multiple Sclerosis and Related Disorders, 2022, 58, 103525.	2.0	36
10	CASPR2â€“IgGâ€“associated autoimmune seizures. Epilepsia, 2022, 63, 709-722.	5.1	14
11	Autoimmune gastrointestinal dysmotility following SARSâ€“CoVâ€“2 infection successfully treated with intravenous immunoglobulin. Neurogastroenterology and Motility, 2022, 34, e14314.	3.0	9
12	Human Leukocyte Antigen Association Study Reveals DRB1*04:02 Effects Additional to DRB1*07:01 in Anti-LGII Encephalitis. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	13
13	<scp>Antiâ€“Neuronal</scp> Nuclear Antibody 3 Autoimmunity Targets Dachshund Homolog 1. Annals of Neurology, 2022, 91, 670-675.	5.3	17
14	Autoimmune/Paraneoplastic Encephalitis Antibody Biomarkers: Frequency, Age, and Sex Associations. Mayo Clinic Proceedings, 2022, 97, 547-559.	3.0	29
15	Cancer and immune-mediated necrotizing myopathy: a longitudinal referral case-controlled outcomes evaluation. Rheumatology, 2022, 62, 281-289.	1.9	5
16	Association of Maintenance Intravenous Immunoglobulin With Prevention of Relapse in Adult Myelin Oligodendrocyte Glycoprotein Antibodyâ€“Associated Disease. JAMA Neurology, 2022, 79, 518.	9.0	39
17	CSF Kappa Free Light Chains: Cutoff Validation for Diagnosing Multiple Sclerosis. Mayo Clinic Proceedings, 2022, 97, 738-751.	3.0	17
18	Adenylate kinase 5 (AK5) autoimmune encephalitis: Clinical presentations and outcomes in three new patients. Journal of Neuroimmunology, 2022, 367, 577861.	2.3	4

#	ARTICLE	IF	CITATIONS
19	Characterisation of TRIM46 autoantibody-associated paraneoplastic neurological syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 196-200.	1.9	20
20	Population-Based Epidemiology Study of Paraneoplastic Neurologic Syndromes. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	29
21	Investigating the Immunopathogenic Mechanisms Underlying <scp>MOGAD</scp>. Annals of Neurology, 2022, 91, 299-300.	5.3	5
22	Anti-complement Agents for Autoimmune Neurological Disease. Neurotherapeutics, 2022, 19, 711-728.	4.4	4
23	IgIV-Spectrin Autoantibodies in 2 Individuals With Neuropathy of Possible Paraneoplastic Origin. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	4
24	Identification of Caveolae-Associated Protein 4 Autoantibodies as a Biomarker of Immune-Mediated Rippling Muscle Disease in Adults. JAMA Neurology, 2022, 79, 808.	9.0	10
25	Longitudinal Retinal Changes in <scp>MOGAD</scp>. Annals of Neurology, 2022, 92, 476-485.	5.3	20
26	A Response to: Letter to the Editor Regarding "Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 ImmunoglobulinG-positive Neuromyelitis Optica Spectrum Disorder". Neurology and Therapy, 2022, 11, 1445-1449.	3.2	2
27	MOG-IgG1 and co-existence of neuronal autoantibodies. Multiple Sclerosis Journal, 2021, 27, 1175-1186.	3.0	29
28	Response to: Eculizumab package insert recommendations for meningococcal vaccinations: call for clarity and a targeted approach for use of the drug in neuromyelitis optica spectrum disorder. CNS Spectrums, 2021, 26, 195-196.	1.2	8
29	Frequency and characteristics of MRI-negative myelitis associated with MOG autoantibodies. Multiple Sclerosis Journal, 2021, 27, 303-308.	3.0	64
30	Critical spinal cord lesions associate with secondary progressive motor impairment in long-standing MS: A population-based case-control study. Multiple Sclerosis Journal, 2021, 27, 667-673.	3.0	7
31	Coexisting systemic and organ-specific autoimmunity in MOG-IgG1-associated disorders versus AQP4-IgG+ NMOSD. Multiple Sclerosis Journal, 2021, 27, 630-635.	3.0	25
32	SMART syndrome: retrospective review of a rare delayed complication of radiation. European Journal of Neurology, 2021, 28, 1316-1323.	3.3	16
33	Variability of cerebrospinal fluid findings by attack phenotype in myelin oligodendrocyte glycoprotein-IgG-associated disorder. Multiple Sclerosis and Related Disorders, 2021, 47, 102638.	2.0	20
34	Paraneoplastic Myeloneuropathies. Neurology, 2021, 96, e632-e639.	1.1	26
35	Brain dysfunction and thyroid antibodies: autoimmune diagnosis and misdiagnosis. Brain Communications, 2021, 3, fcaa233.	3.3	31
36	Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial. Multiple Sclerosis and Related Disorders, 2021, 47, 102641.	2.0	26

#	ARTICLE	IF	CITATIONS
37	Clinical spectrum of high-titre GAD65 antibodies. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 645-654.	1.9	84
38	Seizures and memory impairment induced by patientâ€derived antiâ€Nâ€methylâ€Dâ€aspartate receptor antibodies in mice are attenuated by anakinra, an interleukinâ€1 receptor antagonist. Epilepsia, 2021, 62, 671-682.	5.1	15
39	Paraneoplastic neurological syndrome: an evolving story. Neuro-Oncology Practice, 2021, 8, 362-374.	1.6	5
40	Serum Neurofilament to Magnetic Resonance Imaging Lesion Area Ratio Differentiates Spinal Cord Infarction From Acute Myelitis. Stroke, 2021, 52, 645-654.	2.0	9
41	Leucine Zipper 4 Autoantibody: A Novel Germ Cell Tumor and Paraneoplastic Biomarker. Annals of Neurology, 2021, 89, 1001-1010.	5.3	27
42	Longâ€Term Safety and Efficacy of Eculizumab in Aquaporinâ€4 <scp>IgGâ€Positive NMOSD</scp>. Annals of Neurology, 2021, 89, 1088-1098.	5.3	55
43	Musicogenic epilepsy: Expanding the spectrum of glutamic acid decarboxylase 65 neurological autoimmunity. Epilepsia, 2021, 62, e76-e81.	5.1	13
44	Disability Outcomes in the N-MOMentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	20
45	Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker. Annals of Neurology, 2021, 89, 895-910.	5.3	72
46	Autoimmune encephalitis: proposed recommendations for symptomatic and long-term management. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 897-907.	1.9	66
47	Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 757-768.	1.9	227
48	Clinical Utility of Striational Antibodies in Paraneoplastic and Myasthenia Gravis Paraneoplastic Panels. Neurology, 2021, , 10.1212/WNL.0000000000012050.	1.1	7
49	MOG-IgG Among Participants in the Pediatric Optic Neuritis Prospective Outcomes Study. JAMA Ophthalmology, 2021, 139, 583.	2.5	8
50	Eculizumab in Asian patients with anti-aquaporin-IgG-positive neuromyelitis optica spectrum disorder: A subgroup analysis from the randomized phase 3 PREVENT trial and its open-label extension. Multiple Sclerosis and Related Disorders, 2021, 50, 102849.	2.0	7
51	Clinical Utility of Antiretinal Antibody Testing. JAMA Ophthalmology, 2021, 139, 658.	2.5	18
52	Positive Predictive Value of Myelin Oligodendrocyte Glycoprotein Autoantibody Testing. JAMA Neurology, 2021, 78, 741.	9.0	124
53	Paraneoplastic cochleovestibulopathy: clinical presentations, oncological and serological associations. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1181-1185.	1.9	14
54	Comparison of MRI Lesion Evolution in Different Central Nervous System Demyelinating Disorders. Neurology, 2021, 97, e1097-e1109.	1.1	77

#	ARTICLE	IF	CITATIONS
55	Asian and African/Caribbean AQP4-NMOSD patient outcomes according to self-identified race and place of residence. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 53, 103080.	2.0	7
56	CNS Demyelinating Attacks Requiring Ventilatory Support With Myelin Oligodendrocyte Glycoprotein or Aquaporin-4 Antibodies. <i>Neurology</i> , 2021, 97, e1351-e1358.	1.1	25
57	Myelin-oligodendrocyte glycoprotein antibody-associated disease. <i>Lancet Neurology</i> , The, 2021, 20, 762-772.	10.2	261
58	Brainstem and cerebellar involvement in MOG-IgG-associated disorder versus aquaporin-4-IgG and MS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 384-390.	1.9	55
59	Neurofascin-155 Immunoglobulin Subtypes. <i>Neurology</i> , 2021, 97, .	1.1	17
60	Hope for patients with neuromyelitis optica spectrum disorders “from mechanisms to trials. <i>Nature Reviews Neurology</i> , 2021, 17, 759-773.	10.1	57
61	Neuronal intermediate filament IgGs in CSF: Autoimmune Axonopathy Biomarkers. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 425-439.	3.7	16
62	Diagnostic value of aquaporin-4-IgG live cell based assay in neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021, 7, 205521732110526.	1.0	11
63	Pain and the immune system: emerging concepts of IgG-mediated autoimmune pain and immunotherapies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 177-188.	1.9	44
64	Collapsin Response-Mediator Protein 5 “Associated Retinitis, Vitritis, and Optic Disc Edema. <i>Ophthalmology</i> , 2020, 127, 221-229.	5.2	25
65	Optic neuritis in the era of biomarkers. <i>Survey of Ophthalmology</i> , 2020, 65, 12-17.	4.0	60
66	Myelin Oligodendrocyte Glycoprotein Antibody (MOG-IgG)-Positive Optic Perineuritis. <i>Neuro-Ophthalmology</i> , 2020, 44, 1-4.	1.0	22
67	The frequency of longitudinally extensive transverse myelitis in MS: A population-based study. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 37, 101487.	2.0	35
68	Coexistence of Myelin Oligodendrocyte Glycoprotein and Aquaporin-4 Antibodies in Adult and Pediatric Patients. <i>JAMA Neurology</i> , 2020, 77, 257.	9.0	56
69	Does area postrema syndrome occur in myelin oligodendrocyte glycoprotein-IgG “associated disorders (MOGAD)? <i>Neurology</i> , 2020, 94, 85-88.	1.1	30
70	CRMP5-IgG “Associated Paraneoplastic Myelopathy With PD-L1 Inhibitor Therapy. <i>JAMA Neurology</i> , 2020, 77, 255.	9.0	26
71	Randomized Placebo “Controlled Trial of Intravenous Immunoglobulin in Autoimmune LGI1/CASPR2 Epilepsy. <i>Annals of Neurology</i> , 2020, 87, 313-323.	5.3	106
72	IgM-gammopathy strongly favours immune treatable MMN and MADSAM over ALS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 324-326.	1.9	4

#	ARTICLE	IF	CITATIONS
73	Phenotypic presentations of paraneoplastic neuropathies associated with MAP1B-IgG. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 328-330.	1.9	25
74	Population-Based Incidence of Optic Neuritis in the Era of Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibodies. American Journal of Ophthalmology, 2020, 220, 110-114.	3.3	48
75	Neural Antibody Testing in Patients with Suspected Autoimmune Encephalitis. Clinical Chemistry, 2020, 66, 1496-1509.	3.2	41
76	Expanded Clinical Phenotype, Oncological Associations, and Immunopathologic Insights of Paraneoplastic Kelch-like Protein-11 Encephalitis. JAMA Neurology, 2020, 77, 1420.	9.0	109
77	Application of 2015 Seronegative Neuromyelitis Optica Spectrum Disorder Diagnostic Criteria for Patients With Myelin Oligodendrocyte Glycoprotein IgG-Associated Disorders. JAMA Neurology, 2020, 77, 1572.	9.0	14
78	Improving accuracy of myasthenia gravis autoantibody testing by reflex algorithm. Neurology, 2020, 95, e3002-e3011.	1.1	14
79	<scp>GTPase</scp> Regulator Associated with Focal Adhesion Kinase 1 (<scp>GRAF1</scp>) <scp>Immunoglobulin</scp>-Associated Ataxia and Neuropathy. Movement Disorders Clinical Practice, 2020, 7, 904-909.	1.5	11
80	Long-term Outcomes in Patients With Myelin Oligodendrocyte Glycoprotein Immunoglobulin G-Associated Disorder. JAMA Neurology, 2020, 77, 1575.	9.0	52
81	Neurologic autoimmunity and immune checkpoint inhibitors. Neurology, 2020, 95, e2442-e2452.	1.1	94
82	Association Between Tumor Necrosis Factor Inhibitor Exposure and Inflammatory Central Nervous System Events. JAMA Neurology, 2020, 77, 937.	9.0	78
83	Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients. Multiple Sclerosis and Related Disorders, 2020, 44, 102251.	2.0	110
84	Clinical utility of AQP4-IgG titers and measures of complement-mediated cell killing in NMOSD. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	29
85	Contactin-1 autoimmunity. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, e771.	6.0	15
86	High-resolution epitope mapping of anti-Hu and anti-Yo autoimmunity by programmable phage display. Brain Communications, 2020, 2, fcaa059.	3.3	41
87	Synaptic autoimmunity: new insights into LGI1 antibody-mediated neuronal dysfunction. Brain, 2020, 143, 1622-1625.	7.6	2
88	Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder. Neurology, 2020, 95, e111-e120.	1.1	140
89	Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide. Frontiers in Neurology, 2020, 11, 501.	2.4	216
90	Use of diffusion-weighted imaging to distinguish seizure-related change from limbic encephalitis. Journal of Neurology, 2020, 267, 3337-3342.	3.6	15

#	ARTICLE	IF	CITATIONS
91	International multicenter examination of MOG antibody assays. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.0	180
92	Autoimmune psychosis. <i>Lancet Psychiatry</i> , the, 2020, 7, 122.	7.4	4
93	GFAP IgG associated inflammatory polyneuropathy. <i>Journal of Neuroimmunology</i> , 2020, 343, 577233.	2.3	14
94	The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody. <i>Acta Neuropathologica</i> , 2020, 139, 875-892.	7.7	205
95	Sensitive detection of multiple islet autoantibodies in type 1 diabetes using small sample volumes by agglutination-PCR. <i>PLoS ONE</i> , 2020, 15, e0242049.	2.5	22
96	Glial fibrillary acidic protein IgG related myelitis: characterisation and comparison with aquaporin-4-IgG myelitis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 488-490.	1.9	54
97	Phosphodiesterase 10A IgG. <i>Neurology</i> , 2019, 93, e815-e822.	1.1	52
98	Testing for Myelin Oligodendrocyte Glycoprotein Antibody (MOG-IgG) in typical MS. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 35, 34-35.	2.0	2
99	Paraneoplastic Neurologic Disease. , 2019, , 141-157.		0
100	Kelch-like Protein 11 Antibodies in Seminoma-Associated Paraneoplastic Encephalitis. <i>New England Journal of Medicine</i> , 2019, 381, 47-54.	27.0	169
101	Aquaporin-4 and MOG autoantibody discovery in idiopathic transverse myelitis epidemiology. <i>Neurology</i> , 2019, 93, e414-e420.	1.1	26
102	Amphiphysin-IgG autoimmune neuropathy. <i>Neurology</i> , 2019, 93, e1873-e1880.	1.1	41
103	Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. <i>Lancet, The</i> , 2019, 394, 1352-1363.	13.7	433
104	Autoimmune gait disturbance accompanying adaptor protein-3B2-IgG. <i>Neurology</i> , 2019, 93, e954-e963.	1.1	43
105	Autologous nonmyeloablative hematopoietic stem cell transplantation for neuromyelitis optica. <i>Neurology</i> , 2019, 93, e1732-e1741.	1.1	67
106	Optical coherence tomography is highly sensitive in detecting prior optic neuritis. <i>Neurology</i> , 2019, 92, e527-e535.	1.1	56
107	Aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies in immune-mediated optic neuritis at long-term follow-up. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 1021-1026.	1.9	49
108	Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. <i>New England Journal of Medicine</i> , 2019, 381, 614-625.	27.0	536

#	ARTICLE	IF	CITATIONS
109	GABA _A receptor autoimmunity. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e552.	6.0	42
110	Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders. <i>Brain</i> , 2019, 142, 1310-1323.	7.6	131
111	Antibody Prevalence in Epilepsy and Encephalopathy score: Increased specificity and applicability. <i>Epilepsia</i> , 2019, 60, 367-369.	5.1	43
112	A multicenter comparison of MOG-IgG cell-based assays. <i>Neurology</i> , 2019, 92, e1250-e1255.	1.1	135
113	A mouse model of seizures in anti-N-methyl-D-aspartate receptor encephalitis. <i>Epilepsia</i> , 2019, 60, 452-463.	5.1	46
114	Reader response: Unintended consequences of Mayo paraneoplastic evaluations. <i>Neurology</i> , 2019, 93, 606-606.	1.1	3
115	Overnight loss of pigmented hair in autoimmune autonomic neuropathy treated with IVIg. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e620.	6.0	2
116	Seroprevalence and clinical phenotype of MOG-IgG-associated disorders in Sri Lanka. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, jnnp-2018-320243.	1.9	23
117	Neurochondrin neurological autoimmunity. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, .	6.0	28
118	Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 150-152.	0.9	97
119	Episodic ataxia in CASPR2 autoimmunity. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e536.	6.0	10
120	Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody. <i>JAMA Neurology</i> , 2019, 76, 301.	9.0	243
121	Age is a critical determinant in recovery from multiple sclerosis relapses. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1754-1763.	3.0	33
122	CSF free light chain identification of demyelinating disease: comparison with oligoclonal banding and other CSF indexes. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, 1071-1080.	2.3	45
123	Prevalence of Myelin Oligodendrocyte Glycoprotein and Aquaporin-4 IgG in Patients in the Optic Neuritis Treatment Trial. <i>JAMA Ophthalmology</i> , 2018, 136, 419.	2.5	104
124	Frequency of Aquaporin-4 Immunoglobulin G in Longitudinally Extensive Transverse Myelitis With Antiphospholipid Antibodies. <i>Mayo Clinic Proceedings</i> , 2018, 93, 1299-1304.	3.0	24
125	MRI findings in glutamic acid decarboxylase associated autoimmune epilepsy. <i>Neuroradiology</i> , 2018, 60, 239-245.	2.2	20
126	Glycine receptor modulating antibody predicting treatable stiff-person spectrum disorders. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e438.	6.0	63

#	ARTICLE	IF	CITATIONS
127	Calcium channel autoimmunity: Cerebellar ataxia and Lambert-Eaton syndrome coexisting. Muscle and Nerve, 2018, 58, 29-35.	2.2	7
128	Composite ganglioside autoantibodies and immune treatment response in MMN and MADSAM. Muscle and Nerve, 2018, 57, 1000-1005.	2.2	12
129	ITPR1 autoimmunity: Frequency, neurologic phenotype, and cancer association. Neurology: Neuroimmunology and Neuroinflammation, 2018, 5, e418.	6.0	29
130	Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis. Annals of Neurology, 2018, 83, 166-177.	5.3	479
131	GAD65 autoantibody characteristics in patients with co-occurring type 1 diabetes and epilepsy may help identify underlying epilepsy etiologies. Orphanet Journal of Rare Diseases, 2018, 13, 55.	2.7	23
132	Novel Glial Targets and Recurrent Longitudinally Extensive Transverse Myelitis. JAMA Neurology, 2018, 75, 892.	9.0	17
133	Elevated <sc>LGI</sc> IgG <sc>CSF</sc> index predicts worse neurological outcome. Annals of Clinical and Translational Neurology, 2018, 5, 646-650.	3.7	35
134	Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Autoantibody Status Predict Outcome of Recurrent Optic Neuritis. Ophthalmology, 2018, 125, 1628-1637.	5.2	108
135	LGI1, CASPR2 and related antibodies: a molecular evolution of the phenotypes. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 526-534.	1.9	146
136	Autoimmune CRMP5 neuropathy phenotype and outcome defined from 105 cases. Neurology, 2018, 90, e103-e110.	1.1	86
137	Breast cancer-related paraneoplastic neurologic disease. Breast Cancer Research and Treatment, 2018, 167, 771-778.	2.5	20
138	Purkinje cell cytoplasmic antibody type I (anti-Yo): predictive of gastrointestinal adenocarcinomas in men. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1116-1117.	1.9	16
139	Paraneoplastic neuronal intermediate filament autoimmunity. Neurology, 2018, 91, e1677-e1689.	1.1	50
140	Area postrema syndrome. Neurology, 2018, 91, e1642-e1651.	1.1	129
141	Population-based study of "no evident disease activity" in MS. Neurology: Neuroimmunology and Neuroinflammation, 2018, 5, e495.	6.0	6
142	Antiepileptic drug therapy in autoimmune epilepsy associated with antibodies targeting the leucine-rich glioma-inactivated protein 1. Epilepsia Open, 2018, 3, 348-356.	2.4	26
143	Autoimmune GFAP astrocytopathy: Prospective evaluation of 90 patients in 1 year. Journal of Neuroimmunology, 2018, 321, 157-163.	2.3	136
144	LGI1 and CASPR2 neurological autoimmunity in children. Annals of Neurology, 2018, 84, 473-480.	5.3	53

#	ARTICLE	IF	CITATIONS
145	Myelin Oligodendrocyte Glycoprotein Antibodyâ€“Positive Optic Neuritis: Clinical Characteristics, Radiologic Clues, and Outcome. American Journal of Ophthalmology, 2018, 195, 8-15.	3.3	295
146	Predictors of neural-specific autoantibodies and immunotherapy response in patients with cognitive dysfunction. Journal of Neuroimmunology, 2018, 323, 62-72.	2.3	68
147	Association of MOG-IgG Serostatus With Relapse After Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for MOG-IgGâ€“Associated Disorders. JAMA Neurology, 2018, 75, 1355.	9.0	286
148	Autoimmune septin-5 cerebellar ataxia. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e474.	6.0	38
149	Posttransplant autoimmune encephalitis. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e497.	6.0	24
150	Neuroimmune disorders of the central nervous system in children in the molecular era. Nature Reviews Neurology, 2018, 14, 433-445.	10.1	41
151	Association of Extension of Cervical Cord Lesion and Area Postrema Syndrome With Neuromyelitis Optica Spectrum Disorder. JAMA Neurology, 2017, 74, 359.	9.0	38
152	Microtubuleâ€“associated protein 1<scp>B</scp>: Novel paraneoplastic biomarker. Annals of Neurology, 2017, 81, 266-277.	5.3	73
153	Glial fibrillary acidic protein immunoglobulin <scp>G</scp> as biomarker of autoimmune astrocytopathy: Analysis of 102 patients. Annals of Neurology, 2017, 81, 298-309.	5.3	366
154	Pathogenic implications of cerebrospinal fluid barrier pathology in neuromyelitis optica. Acta Neuropathologica, 2017, 133, 597-612.	7.7	53
155	Ring-enhancing spinal cord lesions in neuromyelitis optica spectrum disorders. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 218-225.	1.9	53
156	Disruption of the leptomeningeal blood barrier in neuromyelitis optica spectrum disorder. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e343.	6.0	55
157	Expanded phenotypes and outcomes among 256 <scp>LGI</scp>1/<scp>CASPR</scp>2â€“<scp>I</scp>g<scp>G</scp>â€“positive patients. Annals of Neurology, 2017, 82, 79-92.	5.3	242
158	Predictive models in the diagnosis and treatment of autoimmune epilepsy. Epilepsia, 2017, 58, 1181-1189.	5.1	120
159	Diagnostic criteria for chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS). Brain, 2017, 140, 2415-2425.	7.6	158
160	PRES leading to the diagnosis of McArdle disease. Journal of Clinical Neuroscience, 2017, 46, 62-64.	1.5	0
161	IgLON5 antibody. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e385.	6.0	172
162	Neuromyelitis optica spectrum disorders and pregnancy: Interactions and management. Multiple Sclerosis Journal, 2017, 23, 1808-1817.	3.0	35

#	ARTICLE	IF	CITATIONS
163	B-cell-targeted therapies in relapsing forms of MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e405.	6.0	10
164	Dacrystic seizures: A cry for help. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e372.	6.0	3
165	Clinical-pathologic correlations in voltage-gated Kv1 potassium channel complex-subtyped autoimmune painful polyneuropathy. <i>Muscle and Nerve</i> , 2017, 55, 520-525.	2.2	20
166	Autoimmune Neurology of the Central Nervous System. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2017, 23, 627-653.	0.8	13
167	A comparison of tissue-based and recombinant protein-based assays for detecting PCA-Tr/DNER-IgG. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e294.	6.0	2
168	Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later. <i>Annals of the New York Academy of Sciences</i> , 2016, 1366, 20-39.	3.8	184
169	Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum. <i>Annals of Neurology</i> , 2016, 79, 775-783.	5.3	263
170	Introduction to autoimmune neurology. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 133, 3-14.	1.8	16
171	Paraneoplastic and idiopathic autoimmune neurologic disorders. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 133, 165-183.	1.8	20
172	Autoimmune AQP4 channelopathies and neuromyelitis optica spectrum disorders. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 133, 377-403.	1.8	69
173	Current and future immunotherapy targets in autoimmune neurology. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 133, 511-536.	1.8	4
174	Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy. <i>JAMA Neurology</i> , 2016, 73, 1297.	9.0	383
175	Autoantibody-Associated Central Nervous System Neurologic Disorders. <i>Seminars in Neurology</i> , 2016, 36, 382-396.	1.4	27
176	P/Q- and N-type calcium-channel antibodies: Oncological, neurological, and serological accompaniments. <i>Muscle and Nerve</i> , 2016, 54, 220-227.	2.2	83
177	Discriminating long myelitis of neuromyelitis optica from sarcoidosis. <i>Annals of Neurology</i> , 2016, 79, 437-447.	5.3	148
178	Clinical utility of testing AQP4-IgG in CSF. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e231.	6.0	113
179	Placebo-controlled study in neuromyelitis optica-Ethical and design considerations. <i>Multiple Sclerosis Journal</i> , 2016, 22, 862-872.	3.0	63
180	Signal recognition particle immunoglobulin g detected incidentally associates with autoimmune myopathy. <i>Muscle and Nerve</i> , 2016, 53, 925-932.	2.2	8

#	ARTICLE	IF	CITATIONS
181	Metabotropic glutamate receptor type 1 autoimmunity. <i>Neurology</i> , 2016, 86, 1009-1013.	1.1	76
182	NMO spectrum disorders: clinical or molecular classification?. <i>Nature Reviews Neurology</i> , 2016, 12, 129-130.	10.1	10
183	Neuromyelitis optica spectrum initially diagnosed as antiphospholipid antibody myelitis. <i>Journal of the Neurological Sciences</i> , 2016, 361, 204-205.	0.6	7
184	Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes. <i>Journal of Neurology</i> , 2016, 263, 140-149.	3.6	60
185	Autoimmune Encephalitis in the ICU: Analysis of Phenotypes, Serologic Findings, and Outcomes. <i>Neurocritical Care</i> , 2016, 24, 240-250.	2.4	60
186	Short Myelitis Lesions in Aquaporin-4-IgG-Positive Neuromyelitis Optica Spectrum Disorders. <i>JAMA Neurology</i> , 2015, 72, 81.	9.0	209
187	Monitoring oligoclonal immunoglobulins in cerebral spinal fluid using microLC-ESI-Q-TOF mass spectrometry. <i>Journal of Neuroimmunology</i> , 2015, 288, 123-126.	2.3	6
188	Basal ganglia T1 hyperintensity in LGI1-autoantibody faciobrachial dystonic seizures. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e161.	6.0	163
189	Poor early relapse recovery affects onset of progressive disease course in multiple sclerosis. <i>Neurology</i> , 2015, 85, 722-729.	1.1	86
190	Rituximab Therapy in Neuromyelitis Optica. <i>JAMA Neurology</i> , 2015, 72, 974.	9.0	3
191	Psychiatric Autoimmunity: N-Methyl-d-Aspartate Receptor IgG and Beyond. <i>Psychosomatics</i> , 2015, 56, 227-241.	2.5	44
192	Asymptomatic myelitis in neuromyelitis optica and autoimmune aquaporin-4 channelopathy. <i>Neurology: Clinical Practice</i> , 2015, 5, 175-177.	1.6	21
193	Autoimmune Epilepsy. <i>Seminars in Neurology</i> , 2015, 35, 245-258.	1.4	53
194	Responses to and Outcomes of Treatment of Autoimmune Cerebellar Ataxia in Adults. <i>JAMA Neurology</i> , 2015, 72, 1304.	9.0	86
195	Diagnostic utility of aquaporin-4 in the analysis of active demyelinating lesions. <i>Neurology</i> , 2015, 84, 148-158.	1.1	49
196	Autoimmune and Paraneoplastic Neurological Disorders. , 2015, , 467-496.		0
197	Relapses and disability accumulation in progressive multiple sclerosis. <i>Neurology</i> , 2015, 84, 81-88.	1.1	92
198	Neural Autoantibody Clusters Aid Diagnosis of Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 3862-3869.	7.0	62

#	ARTICLE	IF	CITATIONS
199	Aquaporin 4 IgG Serostatus and Outcome in Recurrent Longitudinally Extensive Transverse Myelitis. JAMA Neurology, 2014, 71, 48.	9.0	51
200	Hydrocephalus in neuromyelitis optica. Neurology, 2014, 82, 1841-1843.	1.1	22
201	Clinical Reasoning: A 55-year-old man with weight loss, ataxia, and foot drop. Neurology, 2014, 82, e214-9.	1.1	3
202	The neurologic significance of celiac disease biomarkers. Neurology, 2014, 83, 1789-1796.	1.1	54
203	Evaluation of aquaporin-4 antibody assays. Clinical and Experimental Neuroimmunology, 2014, 5, 290-303.	1.0	106
204	Paraneoplastic Neuromyelitis Optica Spectrum Disorder Associated With Metastatic Carcinoid Expressing Aquaporin-4. JAMA Neurology, 2014, 71, 495.	9.0	51
205	Seroprevalence of Aquaporin-4 IgG in a Northern California Population Representative Cohort of Multiple Sclerosis. JAMA Neurology, 2014, 71, 1433.	9.0	73
206	Autoimmune Aquaporin-4 Myopathy in Neuromyelitis Optica Spectrum. JAMA Neurology, 2014, 71, 1025.	9.0	68
207	NMDA receptor encephalitis causing reversible caudate changes on MRI and PET imaging. Neurology: Clinical Practice, 2014, 4, 470-473.	1.6	12
208	Antibodies to AQP4. , 2014, , 605-611.		2
209	DPPX potassium channel antibody. Neurology, 2014, 83, 1797-1803.	1.1	255
210	Investigation of the KIR4.1 potassium channel as a putative antigen in patients with multiple sclerosis: a comparative study. Lancet Neurology, The, 2014, 13, 795-806.	10.2	76
211	Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies. Clinical and Experimental Neuroimmunology, 2014, 5, 175-187.	1.0	18
212	Individualized Rituximab Treatment for Neuromyelitis Optica Spectrum Disorders. JAMA Neurology, 2013, 70, 1102.	9.0	9
213	Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurology, The, 2013, 12, 554-562.	10.2	335
214	Intractable Nausea and Vomiting From Autoantibodies Against a Brain Water Channel. Clinical Gastroenterology and Hepatology, 2013, 11, 240-245.	4.4	49
215	Astrocytic autoantibody of neuromyelitis optica (NMO-IgG) binds to aquaporin-4 extracellular loops, monomers, tetramers and high order arrays. Journal of Autoimmunity, 2013, 40, 21-27.	6.5	67
216	Autoimmune chorea in adults. Neurology, 2013, 80, 1133-1144.	1.1	104

#	ARTICLE	IF	CITATIONS
217	Insights From LGI1 and CASPR2 Potassium Channel Complex Autoantibody Subtyping. JAMA Neurology, 2013, 70, 229.	9.0	170
218	Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology, 2013, 81, 1197-1204.	1.1	206
219	Childhood Onset of Stiff-Man Syndrome. JAMA Neurology, 2013, 70, 1531.	9.0	65
220	Striational antibodies in a paraneoplastic context. Muscle and Nerve, 2013, 47, 585-587.	2.2	33
221	Autoimmune Epilepsy. Archives of Neurology, 2012, 69, 582.	4.5	324
222	Stiff-Man Syndrome and Variants. Archives of Neurology, 2012, 69, 230.	4.5	236
223	Do not treat from CIS onset: evaluate disease course and prognosis first â€“ Yes. Multiple Sclerosis Journal, 2012, 18, 391-393.	3.0	4
224	Effects of Age and Sex on Aquaporin-4 Autoimmunity. Archives of Neurology, 2012, 69, 1039-43.	4.5	91
225	Chronic pain as a manifestation of potassium channel-complex autoimmunity. Neurology, 2012, 79, 1136-1144.	1.1	154
226	Adult-Onset Opsoclonus-Myoclonus Syndrome. Archives of Neurology, 2012, 69, 1598.	4.5	172
227	Diagnostic utility of NMO/AQP4-IgG in evaluating CNS inflammatory disease in Thai patients. Journal of the Neurological Sciences, 2012, 320, 118-120.	0.6	23
228	Potassium channel complex autoimmunity induced by inhaled brain tissue aerosol. Annals of Neurology, 2012, 71, 417-426.	5.3	23
229	Neuronal Voltage-Gated Potassium Channel Complex Autoimmunity in Children. Pediatric Neurology, 2011, 44, 275-281.	2.1	56
230	Psychiatric Manifestations of Voltage-Gated Potassium-Channel Complex Autoimmunity. Journal of Neuropsychiatry and Clinical Neurosciences, 2011, 23, 425-433.	1.8	37
231	Reply: A new case of chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS) with initial normal magnetic resonance imaging. Brain, 2011, 134, e183-e183.	7.6	0
232	Autoimmune Myelopathies. CONTINUUM Lifelong Learning in Neurology, 2011, 17, 776-799.	0.8	8
233	Neural Autoantibody Evaluation in Functional Gastrointestinal Disorders: A Population-Based Caseâ€“Control Study. Digestive Diseases and Sciences, 2011, 56, 1452-1459.	2.3	12
234	Paraneoplastic encephalomyelopathies: pathology and mechanisms. Acta Neuropathologica, 2011, 122, 381-400.	7.7	138

#	ARTICLE	IF	CITATIONS
235	Beneficial Plasma Exchange Response in Central Nervous System Inflammatory Demyelination. Archives of Neurology, 2011, 68, 870.	4.5	173
236	IMMUNOTHERAPY-RESPONSIVE DEMENTIAS AND ENCEPHALOPATHIES. CONTINUUM Lifelong Learning in Neurology, 2010, 16, 80-101.	0.8	35
237	Neural Autoantibody Profile of Primary Achalasia. Digestive Diseases and Sciences, 2010, 55, 307-311.	2.3	59
238	An outbreak of neurological autoimmunity with polyradiculoneuropathy in workers exposed to aerosolised porcine neural tissue: a descriptive study. Lancet Neurology, The, 2010, 9, 55-66.	10.2	48
239	Intractable vomiting as the initial presentation of neuromyelitis optica. Annals of Neurology, 2010, 68, 757-761.	5.3	168
240	Positron Emission Tomographyâ€“Computed Tomography in Paraneoplastic Neurologic Disorders. Archives of Neurology, 2010, 67, 322.	4.5	131
241	Paraneoplastic Jaw Dystonia and Laryngospasm With Antineuronal Nuclear Autoantibody Type 2 (Anti-Ri). Archives of Neurology, 2010, 67, 1109-15.	4.5	84
242	Autoimmune Dementia: Clinical Course and Predictors of Immunotherapy Response. Mayo Clinic Proceedings, 2010, 85, 881-897.	3.0	158
243	Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS). Brain, 2010, 133, 2626-2634.	7.6	316
244	Peripherin-IgG association with neurologic and endocrine autoimmunity. Journal of Autoimmunity, 2010, 34, 469-477.	6.5	31
245	Treatment of Neuromyelitis Optica With Mycophenolate Mofetil. Archives of Neurology, 2009, 66, 1128-33.	4.5	283
246	Diagnosis of Neuromyelitis Spectrum Disorders. Archives of Neurology, 2009, 66, 1134-8.	4.5	87
247	Reversible Extralimbic Paraneoplastic Encephalopathies With Large Abnormalities on Magnetic Resonance Images. Archives of Neurology, 2009, 66, 268-71.	4.5	27
248	Ganglionic Acetylcholine Receptor Autoantibody. Archives of Neurology, 2009, 66, 735-41.	4.5	145
249	STIFF EYES IN STIFF-PERSON SYNDROME. Neurology, 2009, 72, 1877-1878.	1.1	1
250	Prediction of Neuromyelitis Optica Attack Severity by Quantitation of Complement-Mediated Injury to Aquaporin-4â€“Expressing Cells. Archives of Neurology, 2009, 66, 1164-7.	4.5	106
251	Uncertain BENEFIT of early interferon beta-1b treatment. Lancet Neurology, The, 2009, 8, 970-971.	10.2	6
252	Coexistence of myasthenia gravis and serological markers of neurological autoimmunity in neuromyelitis optica. Muscle and Nerve, 2009, 39, 87-90.	2.2	123

#	ARTICLE	IF	CITATIONS
253	Polymyoclonus, Laryngospasm, and Cerebellar Ataxia Associated With Adenocarcinoma and Multiple Neural Cation Channel Autoantibodies. Archives of Neurology, 2009, 66, 1285-7.	4.5	2
254	Autoimmune myelopathy associated with collapsin responseâ€mediator proteinâ€5 immunoglobulin G. Annals of Neurology, 2008, 63, 531-534.	5.3	69
255	Neuromyelitis Optica and Nonâ€Organ-Specific Autoimmunity. Archives of Neurology, 2008, 65, 78-83.	4.5	497
256	Serologic Profiles Aiding the Diagnosis of Autoimmune Gastrointestinal Dysmotility. Clinical Gastroenterology and Hepatology, 2008, 6, 988-992.	4.4	93
257	Aquaporin-4 Autoantibodies in a Paraneoplastic Context. Archives of Neurology, 2008, 65, 629-32.	4.5	177
258	Voltage-Gated Potassium Channel Autoimmunity Mimicking Creutzfeldt-Jakob Disease. Archives of Neurology, 2008, 65, 1341-6.	4.5	166
259	Aquaporin-4â€binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. Journal of Experimental Medicine, 2008, 205, 2473-2481.	8.5	330
260	Neuromyelitis Optica: A New Perspective. Seminars in Neurology, 2008, 28, 095-104.	1.4	31
261	Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain, 2007, 130, 1194-1205.	7.6	650
262	The Pathology of MS. Neurologist, 2007, 13, 45-56.	0.7	95
263	Interferon beta in multiple sclerosis: how much BENEFIT?. Lancet, The, 2007, 370, 363-364.	13.7	12
264	Heterogeneity of presentation and outcome in the Irish rapid-onset dystoniaâ€Parkinsonism kindred. Movement Disorders, 2007, 22, 1325-1327.	3.9	34
265	Neuromyelitis optica: Changing concepts. Journal of Neuroimmunology, 2007, 187, 126-138.	2.3	104
266	The spectrum of neuromyelitis optica. Lancet Neurology, The, 2007, 6, 805-815.	10.2	1,897
267	Glutamic Acid Decarboxylase Autoimmunity With Brainstem, Extrapyramidal, and Spinal Cord Dysfunction. Mayo Clinic Proceedings, 2006, 81, 1207-1214.	3.0	212
268	Inflammatory transverse myelitis: evolving concepts. Current Opinion in Neurology, 2006, 19, 362-368.	3.6	61
269	Neuromyelitis Optica IgG Status in Acute Partial Transverse Myelitis. Archives of Neurology, 2006, 63, 1398.	4.5	72
270	Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Annals of Neurology, 2006, 59, 566-569.	5.3	548

#	ARTICLE	IF	CITATIONS
271	Neuromyelitis Optica Brain Lesions Localized at Sites of High Aquaporin 4 Expression. Archives of Neurology, 2006, 63, 964.	4.5	643
272	Not Every Patient With Multiple Sclerosis Should Be Treated at Time of Diagnosis. Archives of Neurology, 2006, 63, 611.	4.5	54
273	Steroid-Responsive Encephalopathy Associated With Autoimmune Thyroiditis. Archives of Neurology, 2006, 63, 197.	4.5	470
274	Brain Abnormalities in Neuromyelitis Optica. Archives of Neurology, 2006, 63, 390.	4.5	637
275	Amphiphysin autoimmunity: Paraneoplastic accompaniments. Annals of Neurology, 2005, 58, 96-107.	5.3	297
276	IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. Journal of Experimental Medicine, 2005, 202, 473-477.	8.5	1,998
277	Quality of Life Is Favorable for Most Patients With Multiple Sclerosis. Archives of Neurology, 2004, 61, 679.	4.5	116
278	Bright red nuclei. Neurology, 2004, 62, 619-619.	1.1	1
279	Clinical implications of benign multiple sclerosis: A 20-year population-based follow-up study. Annals of Neurology, 2004, 56, 303-306.	5.3	197
280	Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Annals of Neurology, 2004, 56, 715-719.	5.3	303
281	Prevalence of tremor in multiple sclerosis and associated disability in the Olmsted County population. Movement Disorders, 2004, 19, 1482-1485.	3.9	96
282	A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet, The, 2004, 364, 2106-2112.	13.7	2,839
283	Anti-neuronal nuclear autoantibody type 2: Paraneoplastic accompaniments. Annals of Neurology, 2003, 53, 580-587.	5.3	286
284	The Oxfordshire Community Stroke Project classification: Correlation with imaging, associated complications, and prediction of outcome in acute ischemic stroke. Journal of Stroke and Cerebrovascular Diseases, 2003, 12, 1-7.	1.6	79
285	The orpington prognostic scale within the first 48 hours of admission as a predictor of outcome in ischemic stroke. Journal of Stroke and Cerebrovascular Diseases, 2003, 12, 175-181.	1.6	8
286	OKT3 neurotoxicity presenting as akinetic mutism. Transplantation, 2003, 75, 1058-1060.	1.0	28
287	Reversible Myelopathy in a 34-Year-Old Man With Vitamin B12 Deficiency. Mayo Clinic Proceedings, 2002, 77, 291-294.	3.0	39
288	Diagnosis, pathogenesis, and treatment of neuromyelitis optica (NMO) spectrum disorders. , 0, , 614-631.		0

#	ARTICLE	IF	CITATIONS
289	Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): A Review of Clinical and MRI Features, Diagnosis, and Management. Frontiers in Neurology, 0, 13, .	2.4	84